Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1999;84:668-677

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erl, W.
Right arrow Articles by Weber, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erl, W.
Right arrow Articles by Weber, C.
Related Collections
Right arrow Apoptosis
Right arrow Genomics
Right arrow Smooth muscle proliferation and differentiation
(Circulation Research. 1999;84:668-677.)
© 1999 American Heart Association, Inc.


Original Contribution

Nuclear Factor-{kappa}B Regulates Induction of Apoptosis and Inhibitor of Apoptosis Protein-1 Expression in Vascular Smooth Muscle Cells

Wolfgang Erl, Göran K. Hansson, Rainer de Martin, Georg Draude, Kim S. C. Weber, Christian Weber

From the Cardiovascular Research Unit, Center for Molecular Medicine (W.E., G.K.H.), Karolinska Institute, Stockholm, Sweden; the Vienna International Research Cooperation Center (R.d.M.), Wien, Austria; and the Institut für Prophylaxe der Kreislaufkrankheiten (G.D., K.S.C.W., C.W.), München, Germany.

Correspondence to Dr Wolfgang Erl, Cardiovascular Research Unit, CMM L8:03, Karolinska Hospital, S-17176 Stockholm, Sweden. E-mail wolfgang.erl{at}cmm.ki.se


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Apoptosis is important in normal development as well as in diseases such as atherosclerosis. However, the regulation of apoptosis is still not completely understood. We now show that the transcription factor nuclear factor-{kappa}B (NF-{kappa}B) controls the induction of apoptosis in human and rat vascular smooth muscle cells (SMCs). SMCs in high-density culture exhibited a high NF-{kappa}B activity and were insensitive to induction of apoptosis. Inhibition of NF-{kappa}B by adenovirus-mediated overexpression of its inhibitor I{kappa}B{alpha} caused a marked increase in cell death at low but not high cell density. Elevating endogenous I{kappa}B{alpha} levels by inhibiting its degradation with proteasomal inhibitors resulted in induction of apoptosis in low-density SMCs, as detected by increased binding of annexin V, reduced mitochondrial membrane potential, and increased hypodiploid DNA. In high-density cultures, protection against apoptosis was associated with the expression of inhibitor of apoptosis protein-1 (IAP-1). Transfer of I{kappa}B{alpha} reduced human IAP-1 mRNA levels, which suggested that IAP-1 is transcriptionally regulated by NF-{kappa}B. This was confirmed through identification of a motif with NF-{kappa}B–like binding activity in the human IAP-1 promoter region. Moreover, antisense inhibition of IAP-1 sensitized high-density SMCs to the induction of cell death. Together, our data imply that SMCs at high density are protected by an antiapoptotic mechanism that involves increased expression of NF-{kappa}B and IAP-1. Interference with pathways that control the susceptibility to programmed cell death may be helpful in the treatment of diseases where dysregulation of apoptosis is involved, eg, atherosclerosis and restenosis.


Key Words: apoptosis • nuclear factor-{kappa}B • restenosis • gene transfer


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Dysregulated apoptosis has been implicated as a pathogenetic mechanism in a variety of human diseases. Recently, compelling evidence has demonstrated that apoptotic cell death may play an important role in cardiovascular disorders.1 Apoptosis of vascular smooth muscle cells (SMCs) is critically involved in the progression of atherosclerosis and may contribute to the instability of advanced atherosclerotic plaques.1 2 3 4 After angioplasty, the "response to injury program" involves induction of SMC proliferation, which may result in restenosis of the diseased vessel. In this case, apoptosis may aid the remodeling of the injured artery and prevent the development of restenosis.1 4 5 6

Little is known about the mechanisms that regulate apoptotic programs in SMCs. However, recent studies on a variety of cell types, such as B cells, hepatocytes, and osteoclasts,7 8 9 suggest that the transcription factor nuclear factor-{kappa}B (NF-{kappa}B) plays a crucial role in the regulation of apoptosis. These cell types share an important feature with SMCs: a constitutive activity of NF-{kappa}B.7 8 9 10 11 The NF-{kappa}B–like activity in SMCs may be composed of a putative SMC-Rel protein or p65 and p50/Rel protein heterodimers and may be controlled by serum components.10 11 In situ detection of nuclear p65 and p50 has revealed NF-{kappa}B activity within human atheroma, eg, in intimal SMCs but not in undiseased arteries.11 12 Moreover, NF-{kappa}B can be induced in SMCs after arterial balloon injury.13 This activity appears to be essential for the proliferation of SMCs, which is demonstrated by the selective inhibition of SMC growth after microinjection of the NF-{kappa}B inhibitor protein I{kappa}B{alpha} or of oligonucleotides that harbor NF-{kappa}B elements.14 15

Previous studies have not addressed whether the activity of NF-{kappa}B may also affect the viability of SMCs. To test the hypothesis that the inhibition of NF-{kappa}B induces apoptosis in SMCs, we used adenovirus-mediated transfer of I{kappa}B{alpha}, which selectively inhibits NF-{kappa}B,16 as well as inhibitors of proteasomal I{kappa}B degradation.17 18 In this study, we demonstrate that the inhibition of NF-{kappa}B induced apoptosis in human and rat SMCs. However, cells grown at high density were protected from this lethal effect. These cells not only exhibited higher levels of NF-{kappa}B activity but also increased mRNA expression of the recently identified human inhibitor of apoptosis protein-1 (IAP-1).19 The expression of IAP-1 was under the control of NF-{kappa}B, and we discovered an NF-{kappa}B–like binding element in its promoter region. Moreover, antisense inhibition of IAP-1 sensitized high-density SMCs to the induction of cell death. Together, our data suggest that NF-{kappa}B–regulated expression of IAP-1 may protect SMCs from apoptosis.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Culture
Rat aortic smooth muscle cells (rSMCs) were harvested from male Sprague-Dawley rats by enzymatic digestion, as described.20 Human umbilical artery smooth muscle cells (hSMCs) were prepared by cutting umbilical arteries into ring segments of 1- to 2-mm length, removing connective tissue, and incubating these rings in T-25 Falcon Primaria flasks (Becton Dickinson) with medium covering the flask bottom. When cells started to grow after 1 to 2 weeks, the rings were removed, and the remaining colonies were trypsinized and reseeded in T-25 flasks. Human aortic SMCs were purchased from Clonetics Corp. Rat SMCs were grown in DMEM/F12 (all media from Life Technologies) with 10% FCS and 50 µg/mL gentamicin, and human SMCs were grown in Waymouth medium with 15% FCS and antibiotics. Cells were passed every 3 to 5 days (rSMCs) or 1 to 2 weeks (hSMCs) and seeded at a density of 1x104 cells/cm2 for propagation in T-75 flasks or at the specified densities 48 hours before the respective treatment in 24-well plates or T-75 or T-25 flasks. Experiments were performed between passages 5 and 10. All other reagents were from Sigma Chemical Co.

Cell Viability Assays
Cell viability was determined by a modified MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction assay.20 Cells were grown in 24-well plates for 48 hours and treated as indicated, washed with PBS, and 300-µL MTT solution (0.5 mg/mL) in culture medium (0.5% FCS) was added to each well. After 3 hours of incubation at 37°C, MTT was discarded and the purple formazan product in the cells solubilized by addition of acidic isopropanol (0.04 mol/L HCl). After lysing for 10 minutes, 2x100 µL from each well were transferred to a 96-well plate. Absorbance was measured in an ELISA reader at 570 nm, with the absorbance at 690 nm to correct for background, and viability was expressed as the percentage of untreated controls. As an alternative method to analyze cell viability, trypan blue exclusion assays were performed after adherent and nonadherent cells were harvested. To validate the MTT assay as a measure of cell viability, trypan blue exclusion was performed in some experiments in parallel.

Infection of SMCs and Western Blot Analysis
A recombinant adenovirus that contained the coding sequence of I{kappa}B{alpha} under the CMV promoter (rAd.I{kappa}B{alpha}) was constructed as described.16 rSMCs seeded at 1x104 or 10x104 cells/cm2 and hSMCs seeded at 0.4x104 or 4x104 cells/cm2 for 48 hours were washed with PBS and incubated at a multiplicity of infection (MOI) of 500 (plaque forming units, PFU) with rAd.I{kappa}B{alpha} or control adenovirus DL-312 in medium without FCS. After 1 hour at 37°C, the adenovirus was washed off and fresh growth medium was added. Cells were inspected microscopically after 24 and 48 hours. Some infected cells were used for extraction of nuclear protein for electrophoretic mobility shift assay (EMSA) after 24 hours. To analyze the efficiency of transduction, SMCs seeded at the above densities were also infected with rAd encoding the green fluorescent protein (rAd.GFP) as a marker vector at an identical MOI of 500 (PFU). After 48 hours, the fluorescence intensity was analyzed by flow cytometry, and the percentage of GFP-positive SMCs was determined as described.21

To assess I{kappa}B{alpha} expression, SMCs infected with or without rAd.I{kappa}B{alpha} or treated with N{alpha}-p-tosyl-L-lysine chloromethyl ketone (TLCK) were lysed in sample buffer, and whole-cell lysates were separated by 12.5% SDS-PAGE. The amount of protein loaded was adjusted to the number of viable cells. Proteins were then electrophoretically transferred to nitrocellulose membranes. These were blocked for 1 hour at 25°C, incubated with a monoclonal antibody (mAb) to I{kappa}B{alpha} (Santa Cruz Biotechnology), and reacted with a peroxidase-labeled sheep anti–mouse Ig mAb. Blots were developed with chemiluminiscence (ECL, Amersham) and then exposed to X-Omat AR film.

Detection of Apoptosis by Annexin V Staining
Adherent SMCs infected as above were washed with binding buffer and incubated with FITC-labeled annexin V in binding buffer (Annexin V FITC Kit, Immunotech) for 20 minutes at 25°C in the dark. Cells were washed 3 times, harvested by scraping, resuspended in 1 mL PBS with 1.5 mmol/L Ca2+ and 1% FCS, and fixed with 1 mL 2% paraformaldehyde to prevent cell aggregation. SMCs were analyzed by flow cytometry in a FACScan with a single cell gate. After appropriate markers for negative and positive populations were set, the percentage of annexin-V–positive cells was determined.

Analysis of Mitochondrial Membrane Potential
Identification and quantification of apoptotic and nonviable cells was achieved by a multiparameter assay,22 23 which detected a decrease in mitochondrial membrane potential ({Delta}{Psi}) in combination with staining for propidium iodide (PI). To measure {Delta}{Psi}, cells were incubated with 3,3'-dihexyloxacarbocyanine iodide (DiOC; Molecular Probes) at 37°C for 15 minutes (16 nmol/L; 525 nm) followed by immediate analysis of fluorochrome incorporation in a Becton Dickinson FACS Calibur cytometer. Each sample was incubated with PI (1 µg/mL; 600 nm) 10 seconds before analysis to identify viable and nonviable cells. An acquisition gate was set to exclude cell debris and aggregates (R1) and 10,000 cells within this gate were analyzed. In control experiments (data not shown), cells were treated with carbonyl cyanide m-chlorophenylhydrazone (50 µmol/L) to induce {Delta}{Psi} breakdown.

Isolation of Nuclei and DNA Fragmentation Analysis
To detect DNA fragmentation in nuclei of apoptotic cells, we used cell cycle analysis, in which apoptotic cells with a DNA content <2N appear in the sub-G1 region.24 Cells were grown for 48 hours and treated with the proteasomal inhibitors MG-132 (Z-Leu-Leu-Leu-CHO) or lactacystin (Biomol) for 24 hours. The IC50 for inhibition of NF-{kappa}B activity is 3 µmol/L for MG-132 and 10 µmol/L for lactacystin.18 Cultures were scraped and adherent and nonadherent cells were pooled, washed, resuspended in 0.5 mL PBS, and fixed with 5 mL of FACS lysing solution (Becton Dickinson). Cells were then processed with the Cycle Test Plus DNA reagent kit (Becton Dickinson). After cells were washed with 10 mL PBS and 2x1-mL citrate buffer, they were lysed in 250 µL buffer A for 10 minutes and 200 µL buffer B was added for 10 minutes. Nuclei were stained with PI solution for 5 minutes and analyzed in a FACS Calibur with instrument settings from the DNA quality control kit (Becton Dickinson), activated doublet discrimination mode, and a single nuclei gate. Typical histograms were analyzed by manual gating and setting a marker (M1) on the sub-G1 peak.

Preparation of Nuclear Extracts and EMSA
EMSA was performed as described.25 Nonadherent cells were removed and adherent cells were rinsed with PBS and harvested in 1 mL of 20 mmol/L KCl buffer (20 mmol/L HEPES, 22% glycerol, 20 mmol/L KCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L PMSF, 1 µg/mL leupeptin, and 15 µg/mL aprotinin). Isolated nuclei were resuspended in 41 µL of 20 mmol/L KCl buffer, and 39 µL of 0.6 mol/L KCl buffer was added. Nuclear proteins were extracted by incubation on ice for 30 minutes. After cells were centrifuged for 15 minutes at 8000g, supernatants with nuclear proteins were transferred into precooled tubes and protein concentrations were determined spectrophotometrically. Nuclear protein (10 µg) was mixed with double-stranded oligonucleotides that corresponded to the NF-{kappa}B binding motifs 5'-AGTTGAGGGGACTTTCCCAGGC-3' (Santa Cruz) and 5'-AGCAGAGCT-TTCCC-3' (human IAP-1),19 which were labeled with [32P]-dATP with T4 polynucleotide kinase. A 25-fold excess of unlabeled oligonucleotide was used for competition to identify specific binding, whereas competition with unlabeled oligonucleotide with a mutated sequence was ineffective. After the reaction was allowed to bind for 15 minutes, samples were separated on nondenaturating 4% polyacrylamide gels and exposed to x-ray films. To obtain comparable intensities, EMSA with the IAP-1 motif required longer exposure. The absorbance of NF-{kappa}B–specific bands was analyzed by laser densitometry and expressed as optical density (OD)xmm.

Reverse Transcription–Polymerase Chain Reaction
Reverse transcription–polymerase chain reaction (RT-PCR) was essentially performed as described.26 27 RNA was isolated from cells grown in 10-cm dishes by lysis with 7.5 mol/L guanidine-HCl, 3.5 mmol/L N-lauroyl-sarcosine, adjusted to pH 5.2 with 1 mol/L acetic acid, by shearing chromosomal DNA in a needle, followed by phenol and diethylether extraction, and finally by ethanol precipitation. cDNA was produced from total RNA (0.3 µg) by M-MLV reverse transcriptase (Life Technologies). PCR was performed with random hexamers and primers specific for human IAP-1 (sense: 5'-CAGTGGATATTTCCGTGGCT-3', antisense: 5'-TTTCATCTCCTGTG TCT-3') and ß-actin selected from regions with minimal homology to yield products of 676 and 540 bp, respectively.19 24 cDNA was amplified by 32 cycles with Taq DNA polymerase, 48 pmol of human IAP-1 primer, and 36 pmol ß-actin primer in a thermocycler 480 (Perkin-Elmer Cetus) set to the cycle 95°C for 30 seconds, 58°C for 60 seconds, and 72°C for 60 seconds. PCR products were analyzed with 1% agarose gel electrophoresis and were quantified after HPLC separation on a nonporous diethyl-aminoethyl column with a 0.3 to 0.6 mol/L NaCl gradient buffered at pH 9.0 and UV detection at 260 nm (Abimed-Gilson) as described.26 27 The respective peaks appeared at retention times predicted by weight standards, and areas under peaks were integrated. Human IAP-1 mRNA expression was normalized to levels of ß-actin to compensate for variations in mRNA extraction.

Antisense Inhibition of IAP-1
Several phosphorothioate antisense 19-mer oligonucleotides directed against various regions of human IAP-1 mRNA19 were designed according to a recent report28 and suggestions from recent reviews.29 30 Among these, an antisense oligonucleotide directed against a sequence that encompassed the initiation site of human IAP-1 mRNA (5'-GTTCATAAT GAAATGAATG-3') revealed the most obvious effects and was called IAP-1.3, whereas an inversed sequence with corresponding oligonucleotide composition called IAP-1.s3 (5'-GTA AGTAAAGTAATACTTG-3') was used as a control. Human aortic SMCs seeded at 0.4x104 cells/cm2 or 4x104 cells/cm2 were grown for 48 hours and transfected with oligonucleotides (1 µg DNA) in 6-µL Tfx-50 reagent (Promega), with an optimized protocol for human aortic SMCs (Promega notes). Cells were incubated with Tfx/DNA for 1 hour at 37°C in Opti-MEM medium, before normal growth medium (2:1) was added. Cells were then grown for 24 hours and treated with MG-132 (1 µmol/L) in medium with 0.5% FCS. After 24 hours, cells were harvested, and the percentage of dead cells was determined by trypan blue exclusion.

Statistical Analysis
Data are expressed as mean±SD unless otherwise stated and were statistically analyzed by use of Student t test with appropriate Bonferoni corrections, as indicated. Differences with P<0.05 were considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Density-Dependent Sensitivity to Apoptosis in SMCs
The radical scavenger pyrrolidinedithiocarbamate (PDTC), an inhibitor of NF-{kappa}B activation,25 31 has been shown to induce apoptosis in SMCs.32 Interestingly, we found that SMCs seeded at low or high density and grown for 48 hours showed profoundly different sensitivity to induction of cell death by PDTC, as determined by MTT (Figure 1Down). Treatment with PDTC (100 µmol/L) for 24 hours reduced the viability of rSMCs seeded at 1x104 cells/cm2 by 60% and that of human aortic SMCs at 0.4x104 cells/cm2 by 50%. In contrast, rSMCs seeded at 10x104 cells/cm2 or human aortic SMCs at 4x104 cells/cm2 showed no decrease in MTT activity in response to PDTC (Figure 1Down). Thus, SMCs at low but not high density were sensitive to induction of cell death with PDTC, which implied a role of cell density and NF-{kappa}B inhibition in susceptibility to apoptosis.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 1. Effect of PDTC on viability in rat and human SMCs at different densities. Cells were seeded at 1x104 (rSMC low), 10x104 (rSMC high), 0.4x104 (hSMC low), or 4x104 (hSMC high) cells/cm2, grown for 48 hours, and either treated (filled bars) or not treated (open bars) with 100-µmol/L PDTC for 24 hours. Cells were incubated with MTT solution for 3 hours and lysed, and the absorbance was read at 570 nm. MTT viability data were expressed as % of untreated controls and represent mean±SD of 3 independent experiments performed in triplicate.

Overexpression of I{kappa}B{alpha} Induces Apoptosis in SMCs at Low Cell Density
To directly investigate the involvement of NF-{kappa}B in apoptosis of SMCs, cells were seeded at defined densities and subsequently infected with a recombinant adenovirus that expressed I{kappa}B{alpha}. The expression of I{kappa}B{alpha} in rSMCs (seeded at 1x104 or 10x104 cells/cm2) and hSMCs (seeded at 0.4x104 or 4x104 cells/cm2) was analyzed by Western blot analysis(Figure 2ADown). Expression of endogenous I{kappa}B{alpha} was not detectable in uninfected cells by use of a detection system with moderate sensitivity. Overexpression of I{kappa}B{alpha} was achieved by adenovirus-mediated transfer of I{kappa}B{alpha} (Figure 2ADown). The level of I{kappa}B{alpha} expression was similar in lysates from equivalent numbers of infected SMCs and was therefore independent of species or cell density (Figure 2ADown).



View larger version (58K):
[in this window]
[in a new window]
 
Figure 2. Effect of adenoviral I{kappa}B{alpha} overexpression on cell morphology in rat and human SMCs at different densities. A and B, Cells were seeded in 24-well plates at 1x104 or 10x104 cells/cm2 (rSMC) and at 0.4x104 or 4x104 cells/cm2 (hSMC), grown for 48 hours, and either infected or not infected with rAd.I{kappa}B{alpha}, as indicated. After 48 hours, cells were lysed and expression of I{kappa}B{alpha} was analyzed by SDS-PAGE and Western blot analysis (A). Representative photographs were recorded during phase-contrast microscopic (x100) examination (B).

After adenoviral infection, rSMCs seeded at low density (1x104 cells/cm2) revealed little microscopic evidence of cell death after 24 hours of culture (not shown) but were clearly found to undergo cell death after 48 hours of culture when overexpressing I{kappa}B{alpha} (Figure 2BUp). In contrast, rSMCs seeded at high density (10x104 cells/cm2) appeared to be resistant to induction of cell death by overexpression of I{kappa}B{alpha} (Figure 2BUp). Similarly, microscopic examination (Figure 2BUp) revealed that hSMCs seeded at a low density (0.4x104 cells/cm2) were considerably more susceptible to induction of apoptosis than hSMCs seeded at a high density (4x104 cells/cm2). Infection with control adenovirus had no effect on viability at any cell density examined (not shown). To obtain a more quantitative measure of cell death, we harvested hSMCs treated as above after 48 hours of culture; differences in cell viability were analyzed by trypan blue exclusion. Adenovirus-mediated overexpression of I{kappa}B{alpha} induced a marked reduction in the viability of rSMCs and hSMCs seeded at low density, whereas SMCs at high density showed no significant decrease in viability on overexpression of I{kappa}B{alpha} (Figure 3ADown and 3BDown). In contrast, infection with control adenovirus did not affect viability of SMCs at any density (Figure 3ADown and 3BDown). The effects were sustained after prolonged periods of time, ie, 72 hours (data not shown).



View larger version (34K):
[in this window]
[in a new window]
 
Figure 3. Effect of I{kappa}B{alpha} overexpression on viability and apoptosis in rat and human SMCs at different densities. A through D, Cells were seeded at 1x104 or 1x105 cells/cm2 (rSMC) and at 0.4x104 or 4x104 cells/cm2 (hSMC), grown for 48 hours, and either infected or not infected with rAd.I{kappa}B{alpha} (AV-I{kappa}B) or control virus (AV), as indicated. After 48 hours, cells were harvested and the number of viable cells was determined by trypan blue exclusion and expressed as a percentage of untreated control (A and B). In parallel experiments, adherent cells were stained with FITC-conjugated annexin V and analyzed by flow cytometry. Data are given as percent positive for annexin V (C and D). Data represent mean±SD of 3 separate experiments (A through D). E through H, Efficiency of transduction in rat and human SMCs at different densities determined by flow cytometric analysis of rAd.GFP-infected cells. Cells were seeded at 1x104 or 1x105 cells/cm2 (rSMC) and at 0.4x104 or 4x104 cells/cm2 (hSMC), grown for 48 hours, and either infected (dotted lines) or not infected with (solid lines) rAd.GFP, as indicated. After 48 hours, cells were trypsinized and analyzed by flow cytometry. Representative histograms are shown.

To confirm that the reduction of viability was due to apoptosis, we used FITC-conjugated annexin V, which binds to phosphatidylserine that is translocated from the inner to the outer leaflet of the cell membrane and therefore exposed when a cell enters apoptosis.22 33 Consistent with reduced viability, the percentage of annexin V–positive cells was increased by overexpression of I{kappa}B{alpha} in rat and human SMCs seeded at low density, which reflected induction of apoptosis. However, it was not altered in SMCs seeded at high density or by infection with control adenovirus (Figure 3CUp and 3DUp).

To rule out that the observed effects on viability and apoptosis were due to differences in susceptibility to infection, we also infected SMCs at a different density with a recombinant adenovirus expressing GFP (Figure 3EUp through 3H). At an equivalent moi, the percentage of GFP-positive cells after 48 hours was comparable or even higher in high-density (76±2% in rat, 70±5% in human, mean±SD, n=3) compared with low-density (56±3% in rat, 58±2% in human) SMCs. This clearly indicates that high-density cells show similar or better transduction efficiency than subconfluent cells and excludes that the effects we observed were due to differences in susceptibility to infection.

Inhibition of I{kappa}B{alpha} Degradation Induces Apoptotic Death in Low-Density SMCs
To determine whether cell death induced by I{kappa}B{alpha}-mediated NF-{kappa}B inhibition was due to the induction of apoptosis in SMCs, we analyzed sequential alterations in {Delta}{Psi} and in plasma membrane integrity during early stages of apoptosis.22 23 Because the onset of the effects on SMC viability induced by virally transferred I{kappa}B{alpha} could not be precisely timed, we studied SMC apoptosis after treatment with TLCK, an inhibitor of proteolytic I{kappa}B{alpha} degradation.17 TLCK treatment resulted in induction of apoptosis and cell death in rSMCs seeded at low density, as indicated by the percentage of cells with decreased {Delta}{Psi} (DiOClow) or PI+ staining (Figure 4ADown). These effects were more marked in the presence of 0.5% FCS than 10% FCS, whereas induction of cell death could not be detected in rSMCs seeded at high density (data not shown).



View larger version (28K):
[in this window]
[in a new window]
 
Figure 4. Effect of TLCK on apoptosis (A), viability (B), and I{kappa}B{alpha} levels (C) of rat SMCs at low density. A, SMCs seeded at 1x104 cells/cm2 were treated with TLCK (50 µmol/L) for indicated periods, trypsinized, and stained with DiOC (16 nmol/L, 15 minutes, 37°C) for {Delta}{Psi} detection in a FACS Calibur. PI was added to samples 10 seconds before analysis. (1) Forward/side scatter dot plot (FSC-SSC) with region of analyzed cells (R1). (2) Fluorescence (FL1/FL2)-dot plot with quadrant labeling of normal cells (DiOChigh/PI-), apoptotic cells (DiOClow/PI-), and dead cells (PI+). (3) Untreated control. (4) 6 hours or (5) 24 hours of TLCK treatment. Shown is 1 representative of 3 individual experiments with percentage of respective populations given in each quadrant. B, SMCs seeded at indicated densities were grown for 48 hours in medium with 10% FCS and then treated with TLCK at indicated concentrations in medium with 0.5% FCS for 24 hours. Cells were incubated in MTT solution for 3 hours, lysed, and the absorbance was read at 570 nm. MTT viability data were expressed as percent of untreated controls and represent mean±SD of 3 independent experiments performed in triplicate. C, SMCs seeded at 1x104/cm2 were kept untreated (lane 1) or treated with TLCK (50 µmol/L) for 24 hours (lane 2), lysed, and expression of I{kappa}B{alpha} was analyzed by SDS/PAGE and western blot analysis (C).

To confirm that these signs of apoptosis were followed by a reduction in SMC viability after treatment with TLCK, we measured MTT activity. Indeed, we found a dose-dependent decrease in viability induced by TLCK in rSMCs seeded at low but not high density (Figure 4BUp). Similar results were obtained with trypan blue exclusion (data not shown) and in MTT assays after treatment with another proteasome inhibitor, MG-132 (Figure 5Down). This indicates that inhibition of NF-{kappa}B was associated with an induction of apoptosis in SMCs growing at low but not high density and supports the notion that NF-{kappa}B plays a role in protecting SMCs against apoptosis. Western blot analysis revealed that TLCK treatment of low-density SMCs resulted in a similar increase in I{kappa}B levels as that achieved by adenoviral I{kappa}B transfer (Figure 4CUp).



View larger version (21K):
[in this window]
[in a new window]
 
Figure 5. Effect of selective inhibitors of proteasomal I{kappa}B{alpha} degradation on apoptosis (A) and viability (B). A, SMCs were seeded at 1x104 cells/cm2, grown for 48 hours, and treated with MG-132 (3 µmol/L) or lactacystin (10 µmol/L) for 24 hours in medium with 0.5% FCS. Cells were harvested and subjected to nuclear isolation as given in the Cycle Test Plus protocol. PI-stained nuclei were analyzed by flow cytometry for DNA content. Apoptotic cells with a DNA content<2 N appear in the sub-G1 region (M1, 2% for untreated control vs 38% for MG-132 at 3 µmol/L and 9% for lactacystin at 10 µmol/L). Histograms are representative of 2 experiments. B, SMCs seeded at indicated densities were grown for 48 hours and then treated with MG-132 at indicated concentrations in medium with 0.5% FCS for 24 hours. Cells were incubated in MTT solution for 3 hours, lysed, and the absorbance was read at 570 nm. MTT viability data were expressed as % of untreated controls and represent mean±SD of 3 independent experiments.

Cell cycle analysis with DNA staining of isolated nuclei was used as an additional, specific parameter that detected apoptotic cells by their hypodiploid DNA.24 Treatment of low-density SMCs with the proteasome inhibitors MG-132 and lactacystin resulted in an increased percentage of apoptotic cells with a DNA content <2N, as evident by the appearance of a marked peak in the sub-G1 region (Figure 5AUp). A dose-dependent induction of cell death in low but not high-density SMCs by MG-132 treatment was confirmed by parallel MTT assays (Figure 5BUp).

Lower NF-{kappa}B Activity in Apoptosis-Prone Low-Density SMCs
To further elucidate a potential involvement of NF-{kappa}B in the differential susceptibility of SMCs to the induction of apoptosis, EMSA was performed to compare the interactions of an oligonucleotide that contained a classic NF-{kappa}B binding motif with nuclear protein extracts isolated from low- or high-density rSMCs. High-density SMCs exhibited a higher NF-{kappa}B binding activity than low-density cells (Figure 6ADown and 6BDown). Specific binding of NF-{kappa}B was identified by inhibition with an unlabeled competitor oligonucleotide, whereas competition with a mutated oligonucleotide had no effect (Figure 6ADown and 6BDown). In low-density SMCs, treatment with TLCK resulted in a substantial (50%) reduction in NF-{kappa}B activity (Figure 6ADown and 6BDown), which was also inhibited by overexpression of I{kappa}B{alpha} (not shown). Although high-density rSMCs showed a reduction (40%) in NF-{kappa}B activity on TLCK treatment or I{kappa}B{alpha} transfer, the level of NF-{kappa}B activity remained comparable to that of untreated low-density SMCs (Figure 6ADown and 6BDown; not shown). These results suggest that a high constitutive NF-{kappa}B activity may be associated with protection against apoptosis in high-density SMCs, whereas inhibition of NF-{kappa}B may be responsible for the induction of apoptosis in low-density SMCs.



View larger version (30K):
[in this window]
[in a new window]
 
Figure 6. Analysis of NF-{kappa}B activity (A) and densitometric quantification of NF-{kappa}B signals (B) in SMCs at different densities. Rat SMCs were seeded at 1x104 cells/cm2 (low) or at 1x105/cm2 (high) and grown for 48 hours. SMCs were treated with or without TLCK (50 µmol/L) for 24 hours (A). Nuclear extracts were analyzed by EMSA with an orthodox NF-{kappa}B motif. A 25-fold excess of unlabeled oligonucleotide (comp) or oligonucleotide with a mutated sequence (mut) was used for competition. Shown is a representative autoradiogram (A). The absorbance of specific NF-{kappa}B bands on autoradiograms were analyzed and given as ODxmm (B). Data represent mean±SD from 4 independent experiments. *P<0.05 vs untreated high-density cells.

Increased NF-{kappa}B–Dependent IAP-1 Levels in Apoptosis-Resistant High-Density SMCs
To investigate the mechanisms for protection against apoptosis in high-density SMCs, we analyzed the expression of two important inhibitors of apoptosis: bcl-234 and IAP-1, a member of another protein family that suppresses apoptosis.19 Although bcl-2 protein was not detectable (not shown), RT-PCR showed that human IAP-1 mRNA was expressed in hSMCs (Figure 7ADown and 7BDown). The level of IAP-1 mRNA was considerably higher in SMCs growing at high density than at low density (Figure 7ADown and 7BDown). Because this pattern paralleled that observed for NF-{kappa}B activity, we analyzed the effect of I{kappa}B{alpha} overexpression on IAP-1. Adenovirally mediated overexpression of I{kappa}B{alpha} virtually extinguished expression of IAP-1 mRNA in low-density SMCs, whereas IAP-1 mRNA remained detectable in high-density SMCs (Figure 7ADown and 7BDown). This was consistent with differential effects on apoptosis and NF-{kappa}B activity. Inhibition of IAP-1 expression by I{kappa}B{alpha} suggested that IAP-1 may be regulated through the NF-{kappa}B pathway. Therefore, we analyzed the published IAP-1 sequence19 and identified a NF-{kappa}B-like motif (5'-AGCAGAGCTTTCCC-3') in the promoter region at -433 to -424 bp upstream of the transcription initiation site. EMSA with this sequence revealed a NF-{kappa}B–like binding activity, which indicated an unorthodox NF-{kappa}B motif (Figure 7CDown). Thus, the data imply that IAP-1 transcription is promoted by NF-{kappa}B-like elements and that protection against apoptosis in high-density SMCs may involve increased levels of NF-{kappa}B activity and IAP-1 expression.



View larger version (46K):
[in this window]
[in a new window]
 
Figure 7. Analysis of IAP-1 mRNA expression (A and B) and NF-{kappa}B activity (C) in SMCs. Human SMCs (A and B) seeded at 0.4x104 (low) or 4x104 (high) cells/cm2 and rat SMCs (C) seeded at 1x105 cells/cm2 (high) were grown for 48 hours. A and B, SMCs were infected with control virus or rAd.I{kappa}B{alpha} (AV-I{kappa}B{alpha}) and grown for 48 hours. A RT-PCR with specific primers for human IAP-1 was performed, and the PCR products were analyzed by agarose gel electrophoresis and quantitated by HPLC normalized to ß-actin levels. Shown is a photograph from a representative experiment (A) and a bar graph representing mean±SD of 3 independent experiments (B). C, Nuclear extracts from high-density SMCs were analyzed by EMSA to test for binding activity to a putative NF-{kappa}B–like motif in the IAP-1 promoter region (left panel). A 25-fold excess of unlabeled oligonucleotide was used for competition (right panel). Shown is a representative autoradiogram.

Antisense Inhibition of IAP-1 Sensitizes High-Density SMCs to Cell Death Induction
Finally, to support that NF-{kappa}B–regulated IAP-1 expression may causally contribute to the rescue of high-density SMCs from cell death, we performed experiments with an antisense oligonucleotide (IAP-1.3) directed against the initiation site of IAP-1. Transfection of low- or high-density SMCs with either antisense or control oligonucleotides hardly affected viability after 24 hours (not shown). As expected, MG-132 induced cell death in low- but not high-density SMCs (Figure 8Down). Transfection of low-density SMCs with antisense or control oligonucleotides did not affect the induction of cell death by NF-{kappa}B inhibition (Figure 8Down). However, the antisense oligonucleotide IAP-1.3 sensitized apoptosis-resistant high-density SMCs to the induction of cell death, whereas the control oligonucleotide IAP-1.s3 with inversed sequence and corresponding oligonucleotide composition had no effect (Figure 8Down). Consistent with the results based on trypan blue exclusion, transfection of high-density SMCs with IAP-1.3 resulted in a 2-fold increase in the percentage of annexin V-positive cells after treatment with 1 µmol/L MG-132 for 24 hours (data not shown). This demonstrates that IAP-1 can confer protection against cell death in high-density SMCs with high NF-{kappa}B activity.



View larger version (42K):
[in this window]
[in a new window]
 
Figure 8. Antisense inhibition of IAP-1 abolishes protection from cell death in high-density SMCs. A, Nucleotide sequence of the antisense oligonucleotide (IAP-1.3) and of the control oligonucleotide with the inversed sequence but identical nucleotide composition (IAP-1.s3). B, Human aortic SMCs seeded at indicated densities were grown for 48 hours either not transfected (no) or transfected with the oligonucleotides IAP-1.3 (1.3) or IAP-1.s3 (1.s3), grown for 24 hours, and treated or not treated with MG-132 (1 µmol/L). After 24 hours, cells were harvested and the percentage of dead cells was determined by trypan blue exclusion. Data are given as mean±SD from 3 separate experiments. *P<0.05 vs IAP-1.s3.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
SMCs exhibit a constitutive activity of NF-{kappa}B,10 11 which has been shown to promote their proliferation.14 15 However, the mechanism by which NF-{kappa}B controls the expansion of SMC populations remains unclear. We now show that (1) induction of apoptosis depends on the density of SMCs; (2) high-density SMCs are resistant to apoptosis and express a high constitutive NF-{kappa}B activity, whereas low-density SMCs are prone to undergo apoptosis and exhibit less NF-{kappa}B activity, (3) inhibition of NF-{kappa}B by overexpressing its inhibitor I{kappa}B{alpha} or by preventing I{kappa}B{alpha} degradation results in apoptosis in low-density SMCs; (4) overrepression of I{kappa}B{alpha} prevents expression of antiapoptotic IAP-1; (5) NF-{kappa}B is thus required for expression of IAP-1, which contains a NF-{kappa}B–like motif in its promoter region; and (6) protection of high-density SMCs from the induction of cell death is mediated by IAP-1. Together, these data indicate that NF-{kappa}B may promote SMC growth by modulating apoptosis, that the antiapoptotic machinery develops in parallel with increasing SMC density, and that NF-{kappa}B–regulated expression of IAP-1 is an important component of this machinery in SMCs.

Inhibition of NF-{kappa}B by overexpression of I{kappa}B{alpha} resulted in a selective induction of apoptotic cell death in rat and human SMCs, as shown by trypan blue exclusion and annexin V binding, which was dependent on cell density, ie, restricted to low density. In fact, SMCs seeded at high density appeared to be protected from the induction of apoptosis, despite equivalent levels of I{kappa}B{alpha} expression after adenoviral transfer at both densities. Infection with rAd.GFP indicated that these effects were not due to differences in transduction efficiency between high- and low-density cells. This extends previous findings that inhibition of NF-{kappa}B can induce apoptosis or cell death in different cell types.7 8 9 35 36 In contrast to drug-mediated NF-{kappa}B inhibition or microinjection of I{kappa}B{alpha},7 8 9 adenovirus-mediated gene transfer of I{kappa}B{alpha} enabled us to inhibit NF-{kappa}B–like activities specifically and effectively in a large proportion of the cell population. Our data imply that a constitutive NF-{kappa}B activity protects against apoptosis in high-density SMCs. A sufficient NF-{kappa}B activity may thus be crucial to maintain and support both SMC proliferation and survival.

To detect the effects of NF-{kappa}B inhibition on SMC viability, we analyzed trypan blue exclusion, which is widely used in studies of apoptosis.34 Mitochondrial dysfunction is an initial step in the death program, and a reduction in {Delta}{Psi} is a specific marker to detect early apoptotic changes.22 23 Because the characteristic cleavage of DNA into nucleosome-sized fragments, considered as a hallmark of apoptosis, is a late event in the apoptotic process and does not occur in all cell types,37 {Delta}{Psi} was measured in rSMCs. In this setting, we used TLCK, an inhibitor of NF-{kappa}B activity that prevents I{kappa}B{alpha} degradation and thus increases cytoplasmic I{kappa}B{alpha} levels more rapidly than adenovirus-mediated transfer of I{kappa}B{alpha}, which required more than 24 hours for the onset of detectable effects in human and rat SMCs. Western blot and trypan blue exclusion analysis after adenoviral I{kappa}B{alpha} transfer or TLCK treatment revealed similar efficacy in increasing I{kappa}B{alpha} levels and inducing cell death in low-density SMCs. Treatment of SMCs with TLCK resulted in sequential alterations of {Delta}{Psi} and plasma membrane integrity, ie, a reduced staining with DiOC accompanied by an increase in PI+ cells. Consistent with results after I{kappa}B{alpha} overexpression, TLCK treatment did not reduce viability in high-density SMCs. With the use of fluorescence staining of isolated nuclei to detect DNA degradation in apoptotic cells, we confirmed that MG-132 and lactacystin, which are more potent and selective inhibitors of proteasomal I{kappa}B{alpha} degradation than TLCK, induce apoptosis in low-density SMCs.

Viability depends on the balance between apoptosis and proliferation. Because apoptosis is a kinetic and transient process that ultimately leads to cell death, a moderate increase in the percentage of apoptotic cells at a given time (as evident in the apoptosis assays used) can cumulatively result in a 50% reduction of viability, as seen in MTT assays over 24 hours.

The lower susceptibility to apoptosis in high-density cells was associated with a higher constitutive NF-{kappa}B–like activity, which provides further evidence that NF-{kappa}B is involved in the regulation of programmed cell death. Moreover, this higher NF-{kappa}B was less clearly inhibited by increasing levels of I{kappa}B{alpha} in high-density cells. This supports the notion that a high constitutive NF-{kappa}B activity may protect against apoptosis. Several groups have shown an essential role for NF-{kappa}B, in particular its p65 subunit, in the prevention of tumor necrosis factor-{alpha} (TNF-{alpha})–induced apoptosis.38 39 40 This infers a negative feedback loop by which NF-{kappa}B activation that results from TNF-{alpha} signaling may counteract TNF-{alpha}-induced cell death programs and clearly separates the apoptosis-inducing potential of TNF-{alpha} from NF-{kappa}B activation. We now demonstrate that a constitutive NF-{kappa}B activity, which may be independent of agonist or cytokine-induced death signals, favors survival programs in SMCs. The inhibition by I{kappa}B{alpha} indicates that p65 and c-Rel rather than p50 are candidates likely to mediate this activity. This is supported by the ineffectiveness of the p50-specific inhibitor SN50 to induce apoptosis (W.E. et al., unpublished data). It is also possible that specific factors of the Rel/NF-{kappa}B family are involved in mediating different pathways. In fact, such a distinction has recently been reported in B lymphocytes.41

To elucidate potential mechanisms of protection, we studied mRNA expression of human IAP-1, a member of a novel class of molecules, the inhibitor of apoptosis proteins of nonviral origin,42 which can protect against apoptosis by inhibiting cell-death caspases.43 44 45 High-density hSMCs revealed an increased expression of IAP-1 mRNA, which could be responsible for protection against apoptosis in our study. Similarly, increased expression of IAP-2 and X chromosome–linked IAP has been found in high- versus low-density SMCs (W.E. et al, unpublished data, 1998). In contrast, we did not detect expression of anti–apoptotic bcl-2 protein in SMCs at any density, although the related bcl-xL has been shown to be present in neointima, and its inhibition induced apoptosis and regression of vascular disease.46 This complies with results that IAPs and bcl-2 confer protection in separate but overlapping pathways.19 Overexpression of I{kappa}B{alpha} blocked IAP-1 mRNA expression in low-density SMCs, but reduced its expression only in high-density cells. This parallels effects of I{kappa}B{alpha} overexpression on SMC viability and further infers a protective role of IAP-1. Our data are consistent with recent findings in endothelial cells in which cytokine-induced IAP expression is dependent on NF-{kappa}B and overexpression of X chromosome–linked IAP protected against TNF-{alpha}–induced apoptosis.24 The conclusion that IAP-1 expression is regulated by NF-{kappa}B in SMCs is supported by a report that shows that IAP-1 mediates the antiapoptotic activity of v-Rel.47 Notably, we found a NF-{kappa}B–like binding activity to a newly identified motif within the human IAP-1 promoter region in high-density hSMCs. Other studies have found IAP-2 but not IAP-1 to be under the control of NF-{kappa}B,48 which indicates that IAP genes may be differentially regulated by NF-{kappa}B in distinct cellular systems. Our present results suggest that the expression of IAP-1 may be regulated by engagement of a NF-{kappa}B–like promoter element. This supports recent findings that induction of IAP-1 and IAP-2 serves as an important mechanism by which NF-{kappa}B prevents apoptosis.45 In addition to the transfer of IAP of viral or bacterial origin, such NF-{kappa}B–dependent mechanisms may essentially contribute to accomplish host cell survival during bacterial or viral infections.42 49 We now directly demonstrate by antisense inhibition that IAP-1 confers protection against cell death in high-density SMCs with high NF-{kappa}B activity. This suggests that IAP-1 plays a crucial role in controlling apoptosis in these cells. Recent reports have demonstrated that expression of IAP-1 or IAP-2 alone was not sufficient to rescue cells with inactive NF-{kappa}B from TNF-induced apoptosis,45 48 which suggests that multiple antiapoptotic gene products that are activated by NF-{kappa}B function cooperatively to achieve optimal protection against apoptosis. Our findings in hSMCs that the suppression of IAP-1 results in a remarkable sensitization to induction of cell death support a prominent role of IAP-1 among the components of this antiapoptotic machinery and may indicate that a disruption of the protective network can affect resistance to apoptosis.

The finding that inhibition of constitutive NF-{kappa}B induces apoptosis in low-density SMCs suggests that the death program is a default pathway that is modulated by cellular NF-{kappa}B activity. A high frequency of apoptosis may be important to permit high cell turnover and tissue remodeling in growing cell populations. These situations may be mimicked in a low density culture, whereas a high-density culture may reflect a more stable situation in normal, adult tissue. NF-{kappa}B may be a signal linking cell density to apoptosis and thus to cell turnover. Pathological tissue growth can be controlled by inducing apoptosis, and transfer of I{kappa}B{alpha} may therefore be a promising way to prevent restenosis caused by excessive SMC proliferation after angioplasty and arterial injury. Also, evidence for activated NF-{kappa}B has been provided in intimal SMCs of human atheroma but not nonatherosclerotic arteries.11 12 The activation of NF-{kappa}B in SMCs after balloon injury has been associated with intimal lesion formation and inflammatory responses.13 Adenovirus-mediated gene transfer by pressure-assisted delivery of constitutive endothelial nitric oxide synthase in balloon-injured arteries has been shown to allow virus penetration through the elastic laminae to deeper layers and to reduce SMC proliferation and neointima formation.50 Recently, adenoviral gene transfer of fas ligand to the vessel wall has been shown to induce apoptosis in fas-bearing SMCs, thereby inhibiting balloon injury-induced neointima formation in rat carotid arteries.51 Since nitric oxide can induce apoptosis in SMCs and has been shown to inhibit NF-{kappa}B mobilization in vascular cells,52 53 54 it may induce SMC apoptosis by inhibiting NF-{kappa}B activity. The feasibility of gene transfer to adult human vessels has recently been demonstrated;55 however, high titers of infection may cause activation of vascular endothelium.56 Hence, adenoviral I{kappa}B{alpha} overexpression and antiinflammatory and antioxidative agents that inhibit NF-{kappa}B mobilization may act in concert to induce SMC apoptosis and to inhibit endothelial activation.16 25 26 57 This may attenuate inflammatory reactions after angioplasty or adenoviral gene transfer, which improves the prevention of neointima formation and contributes to the benefits of NF-{kappa}B inhibition.

In conclusion, the sensitivity to induction of apoptosis in exponentially proliferating low-density SMCs contrasts strongly with the resistance to apoptosis of high-density SMCs with a "resting" phenotype. Such differences in the regulation of cell death and turnover could have important implications for the prevention of restenosis in diseased vessels. Considering the limited success of preventing restenosis in humans by inhibiting SMC proliferation, the key role of NF-{kappa}B and IAP-1 in the regulation of SMC apoptosis demonstrated herein offers an attractive new target for the therapeutic control of neointima formation.


*    Acknowledgments
 
This study was supported by the Swedish MRC (grant 6816), Heart-Lung Foundation and Cancer Research, Deutsche Forschungs-gemeinschaft (grant Er 270/1-1 to W.E. and We 1913/2-1 to C.W.), August-Lenz Stiftung (K.S.C.W.), and an exchange program of Deutscher Akademischer Austauschdienst. We thank A. Olsson for performing EMSA.

Received August 10, 1998; accepted January 7, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res. 1998;82:1111–1129.[Free Full Text]

2. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1ß converting enzyme. Am J Pathol. 1995;147:251–266.[Abstract]

3. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266–2274.

4. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995;147:267–277.[Abstract]

5. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703–2711.[Abstract/Free Full Text]

6. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis: focus on cytomegalovirus. Lancet. 1996;348(suppl I):13–17.

7. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH, Sonenshein GE. Inhibition of NF-{kappa}B/Rel induces apoptosis of murine B cells. EMBO J. 1996;15:4682–4690.[Medline] [Order article via Infotrieve]

8. Bellas RE, FitzGerald MJ, Fausto N, Sonenshein GE. Inhibition of NF-{kappa}B activity induces apoptosis in murine hepatocytes. Am J Physiol. 1997;151:891–896.

9. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S. NF-{kappa}B inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resortion by these cells. FEBS Lett. 1997;410:297–300.[Medline] [Order article via Infotrieve]

10. Lawrence R, Chang LJ, Siebenlist U, Bressler P, Sonenshein GE. Vascular smooth muscle cells express a constitutive NF-{kappa}B-like activity. J Biol Chem. 1994;269:28913–28918.[Abstract/Free Full Text]

11. Bourcier T, Sukhova G, Libby P. The nuclear factor-{kappa}B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem. 1997;272:15817–15824.[Abstract/Free Full Text]

12. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715–1722.[Medline] [Order article via Infotrieve]

13. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF-{kappa}B and I{kappa}B system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1. Am J Pathol. 1997;151:1085–1095.[Abstract]

14. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-{kappa}B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest. 1995;96:2521–2527.

15. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-{kappa}B inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun. 1995;213:827–836.[Medline] [Order article via Infotrieve]

16. Wrighton CJ, Hofer-Warbinek R, Moll T, Eytner R, Bach FH, de Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of I{kappa}B{alpha}, an inhibitor of the transcription factor NF-{kappa}B. J Exp Med. 1996;183:1013–1022.[Abstract/Free Full Text]

17. Henkel T, Machleidt T, Alkalay I, Krönke M, Ben-Niriah Y, Baeuerle PA. Rapid proteolysis of I{kappa}B{alpha} is necessary for activation of transcription factor NF-{kappa}B. Nature. 1993;365:182–185.[Medline] [Order article via Infotrieve]

18. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem (Tokyo). 1996;119:572–576.[Abstract/Free Full Text]

19. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda J, MacKenzie A, Korneluk RG. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349–353.[Medline] [Order article via Infotrieve]

20. Yan Z, Hansson GK. Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. Circ Res. 1998;82:21–29.[Abstract/Free Full Text]

21. de Martin R, Raidl M, Hofer E, Binder BR. Adenovirus-mediated expression of green fluorescent protein. Gene Ther. 1997;4:493–495.[Medline] [Order article via Infotrieve]

22. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995;182:367–377.[Abstract/Free Full Text]

23. Castedo M, Hirsch T, Susin SA, Zamzami N, Marchetti P, Macho A, Kroemer G. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol. 1996;157:512–521.[Abstract]

24. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. NF-{kappa}B regulated X-chromosomal-linked iap gene expression protects endothelial cells from TNF-{alpha} induced apoptosis. J Exp Med. 1998;188:211–216.[Abstract/Free Full Text]

25. Weber C, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HW, Weber PC. Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-{kappa}B mobilization and induction of vascular cell adhesion molecule 1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb. 1994;14:1665–1673.[Abstract/Free Full Text]

26. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-{kappa}B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914–1917.[Abstract/Free Full Text]

27. Weber C, Negrescu E, Erl W, Pietsch A, Frankenberger M, Ziegler-Heitbrock HWL, Siess W, Weber PC. Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. J Immunol. 1995;155:445–451.[Abstract]

28. Tu G, Cao Q, Zhou F, Israel Y. Tetranucleotide GGGA motif in primary RNA transcripts: novel target site for antisense design. J Biol Chem. 1998;273:25125–25131.[Abstract/Free Full Text]

29. Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci. 1998;23:45–50.[Medline] [Order article via Infotrieve]

30. Stein CA. How to design an antisense oligodeoxynucleotide experiment: a consensus approach. Antisense Nucleic Acid Drug Dev. 1998;8:129–132.[Medline] [Order article via Infotrieve]

31. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor {kappa}B activation in intact cells. J Exp Med. 1992;175:1181–1194.[Abstract/Free Full Text]

32. Tsai JC, Jain M, Hsieh CM, Lee WS, Yoshizumi M, Patterson C, Perrella MA, Cooke C, Wang H, Haber E, Schlegel R, Lee ME. Induction of apoptosis by pyrrolidine dithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem. 1996;271:3667–3670.[Abstract/Free Full Text]

33. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometry detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415–1424.[Abstract/Free Full Text]

34. Hockenberry DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241–251.[Medline] [Order article via Infotrieve]

35. Mannick EE, Mishra J, Marque J, Clavell M, Miller MJ, Oliver PD. Inhibitors of nuclear factor {kappa}B cause apoptosis in cultured macrophages. Med Inflamm. 1997;6:225–232.

36. Taglialatela G, Robinson R, Perez-Polo JR. Inhibition of nuclear factor {kappa}B activity induces nerve growth factor-resistant apoptosis in PC12 cells. J Neurosci Res. 1997;47:155–162.[Medline] [Order article via Infotrieve]

37. Cohen GM, Sun XM, Snowden RT, Dinsdale D, Skilletter DN. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J. 1992;286:331–334.

38. Beg AA, Baltimore D. An essential role for NF-{kappa}B in preventing TNF-{alpha}-induced cell death. Science. 1996;274:782–784.[Abstract/Free Full Text]

39. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis potentiation by inhibition of NF-{kappa}B. Science. 1996;274:784–787.[Abstract/Free Full Text]

40. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-{alpha}-induced apoptosis by NF-{kappa}B. Science. 1996;274:787–789.[Abstract/Free Full Text]

41. Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, Gerondakis S. B lymphocytes differentially use the rel and nuclear factor {kappa}B1 transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med. 1998;187:663–674.[Abstract/Free Full Text]

42. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83:1243–1252.[Medline] [Order article via Infotrieve]

43. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300–304.[Medline] [Order article via Infotrieve]

44. Seshagiri S, Miller LK. Baculovirus inhibitors of apoptosis (IAPs) block activation of Sf-caspase-1. Proc Natl Acad Sci U S A. 1997;94:13606–13611.[Abstract/Free Full Text]

45. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-{kappa}B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281:1680–1683.[Abstract/Free Full Text]

46. Pollman MJ, Hall JL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-xL expression induces apoptosis and regression of vascular disease. Nat Med. 1998;4:222–227.[Medline] [Order article via Infotrieve]

47. You M, Ku PT, Hrdlickova R, Bose HR. Ch-Iap1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol. 1997;17:7328–7341.[Abstract]

48. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-{kappa}B control. Proc Natl Acad Sci U S A. 1997;94:10057–10062.[Abstract/Free Full Text]

49. Clifton DR, Goss RA, Sahni SK, van Antwerp D, Baggs RB, Marder VJ, Silverman DJ, Sporn LA. NF-{kappa}B-dependent inhibition of apoptosis is essential for host cell survival during Rickettsia rickettsii infection. Proc Natl Acad Sci U S A. 1998;95:4646–4651.[Abstract/Free Full Text]

50. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt N, Haustermans C, Zoldhelyi P, Gerard RD, Collen D. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97:1274–1281.[Abstract/Free Full Text]

51. Sata M, Perlman H, Muruve DA, Silver M, Ikebe M, Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc Natl Acad Sci U S A. 1998;95:1213–1217.[Abstract/Free Full Text]

52. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79:748–756.[Abstract/Free Full Text]

53. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-{gamma}, tumor necrosis factor-{alpha}, and interleukin-1ß. Arterioscler Thromb Vasc Biol. 1996;16:19–27.[Abstract/Free Full Text]

54. Shin WS, Hong YH, Peng HB, De Caterina R, Libby P, Liao JK. Nitric oxide attenuates vascular smooth muscle cell activation by interferon-{gamma}: the role of constitutive NF-{kappa}B activity. J Biol Chem. 1996;271:11317–11324.[Abstract/Free Full Text]

55. Rekhter MD, Simari RD, Work CW, Nabel GJ, Nabel EG, Gordon D. Gene transfer into normal and atherosclerotic human blood vessels. Circ Res. 1998;82:1243–1252.[Abstract/Free Full Text]

56. Channon KM, Qian H, Youngblood SA, Olmez E, Shetty GA, Neplioueva V, Blazing MA, George SE. Acute host-mediated endothelial injury after adenovirus gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res. 1998;82:1253–1262.[Abstract/Free Full Text]

57. Erl W, Weber C, Wardemann C, Weber PC. {alpha}-Tocopheryl succinate inhibits monocytic cell adhesion to endothelial cells by suppressing nuclear factor-{kappa}B mobilization. Am J Physiol. 1997;273:H634–H640.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
A. Orlandi, A. Ferlosio, G. Arcuri, M. G. Scioli, S. De Falco, and L. G. Spagnoli
Flt-1 expression influences apoptotic susceptibility of vascular smooth muscle cells through the NF-{kappa}B/IAP-1 pathway
Cardiovasc Res, September 16, 2009; (2009) cvp288v2.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. W. Orr, M. Y. Lee, J. A. Lemmon, A. Yurdagul Jr, M. F. Gomez, P. D. Schoppee Bortz, and B. R. Wamhoff
Molecular Mechanisms of Collagen Isotype-Specific Modulation of Smooth Muscle Cell Phenotype
Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 225 - 231.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Aoki, H. Kataoka, M. Shimamura, H. Nakagami, K. Wakayama, T. Moriwaki, R. Ishibashi, K. Nozaki, R. Morishita, and N. Hashimoto
NF-{kappa}B Is a Key Mediator of Cerebral Aneurysm Formation
Circulation, December 11, 2007; 116(24): 2830 - 2840.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. M. Kim, H.-O. Pae, M. Zheng, R. Park, Y.-M. Kim, and H.-T. Chung
Carbon Monoxide Induces Heme Oxygenase-1 via Activation of Protein Kinase R Like Endoplasmic Reticulum Kinase and Inhibits Endothelial Cell Apoptosis Triggered by Endoplasmic Reticulum Stress
Circ. Res., October 26, 2007; 101(9): 919 - 927.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Orlandi, A. Francesconi, M. Marcellini, A. Di Lascio, and L. G. Spagnoli
Propionyl-L-carnitine Reduces Proliferation and Potentiates Bax-related Apoptosis of Aortic Intimal Smooth Muscle Cells by Modulating Nuclear Factor-{kappa}B Activity
J. Biol. Chem., February 16, 2007; 282(7): 4932 - 4942.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. von Wnuck Lipinski, P. Keul, N. Ferri, S. Lucke, G. Heusch, J. W. Fischer, and B. Levkau
Integrin-Mediated Transcriptional Activation of Inhibitor of Apoptosis Proteins Protects Smooth Muscle Cells Against Apoptosis Induced by Degraded Collagen
Circ. Res., June 23, 2006; 98(12): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. A. Pfrommer, W. Erl, and P. C. Weber
Docosahexaenoic acid induces ciap1 mRNA and protects human endothelial cells from stress-induced apoptosis
Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2178 - H2186.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. Chao, Y. Shen, L. Li, H. Zhao, S. E. Meiler, S. A. Cook, and A. Rosenzweig
Fas-associated death-domain protein inhibits TNF-{alpha} mediated NF-{kappa}B activation in cardiomyocytes
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2073 - H2080.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
F. B. Mehrhof, R. Schmidt-Ullrich, R. Dietz, and C. Scheidereit
Regulation of Vascular Smooth Muscle Cell Proliferation: Role of NF-{kappa}B Revisited
Circ. Res., May 13, 2005; 96(9): 958 - 964.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
V. Esteban, M. Ruperez, E. Sanchez-Lopez, J. Rodriguez-Vita, O. Lorenzo, H. Demaegdt, P. Vanderheyden, J. Egido, and M. Ruiz-Ortega
Angiotensin IV Activates the Nuclear Transcription Factor-{kappa}B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells
Circ. Res., May 13, 2005; 96(9): 965 - 973.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H. Li, S. Telemaque, R. E. Miller, and J. D. Marsh
High Glucose Inhibits Apoptosis Induced by Serum Deprivation in Vascular Smooth Muscle Cells via Upregulation of Bcl-2 and Bcl-xl
Diabetes, February 1, 2005; 54(2): 540 - 545.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
E. W. Raines, K. J. Garton, and N. Ferri
Beyond the Endothelium: NF-{kappa}B Regulation of Smooth Muscle Function
Circ. Res., April 2, 2004; 94(6): 706 - 708.
[Full Text] [PDF]


Home page
Circ. Res.Home page
U. Zeiffer, A. Schober, M. Lietz, E. A. Liehn, W. Erl, N. Emans, Z.-q. Yan, and C. Weber
Neointimal Smooth Muscle Cells Display a Proinflammatory Phenotype Resulting in Increased Leukocyte Recruitment Mediated by P-Selectin and Chemokines
Circ. Res., April 2, 2004; 94(6): 776 - 784.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Monaco and E. Paleolog
Nuclear factor {kappa}B: a potential therapeutic target in atherosclerosis and thrombosis
Cardiovasc Res, March 1, 2004; 61(4): 671 - 682.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. Verma, M. V. Badiwala, R. D. Weisel, S.-H. Li, C.-H. Wang, P. W. M. Fedak, R.-K. Li, and D. A. G. Mickle
C-reactive protein activates the nuclear factor-{kappa}B signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis
J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1886 - 1891.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. W. Xiao, X. Yan, Y. Li, S. A. G. Reddy, and B. K. Tsang
Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor {alpha} Is a Consequence of Nuclear Factor {kappa}B-Mediated Induction of Fas-Associated Death Domain-Like Interleukin-1{beta}-Converting Enzyme-Like Inhibitory Protein
Endocrinology, February 1, 2003; 144(2): 623 - 630.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Vaage and G. Valen
Preconditioning and cardiac surgery
Ann. Thorac. Surg., February 1, 2003; 75(2): S709 - 714.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
V. Poulaki, C. S. Mitsiades, A. M. Joussen, A. Lappas, B. Kirchhof, and N. Mitsiades
Constitutive Nuclear Factor-{kappa}B Activity Is Crucial for Human Retinoblastoma Cell Viability
Am. J. Pathol., December 1, 2002; 161(6): 2229 - 2240.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. Martinet, D. M. Schrijvers, G. R.Y. De Meyer, J. Thielemans, M. W.M. Knaapen, A. G. Herman, and M. M. Kockx
Gene Expression Profiling of Apoptosis-Related Genes in Human Atherosclerosis: Upregulation of Death-Associated Protein Kinase
Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 2023 - 2029.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Aragno, R. Mastrocola, E. Brignardello, M. Catalano, G. Robino, R. Manti, M. Parola, O. Danni, and G. Boccuzzi
Dehydroepiandrosterone Modulates Nuclear Factor-{kappa}B Activation in Hippocampus of Diabetic Rats
Endocrinology, September 1, 2002; 143(9): 3250 - 3258.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Wang, S. Chan, and B. K. Tsang
Involvement of Inhibitory Nuclear Factor-{kappa}B (NF{kappa}B)-Independent NF{kappa}B Activation in the Gonadotropic Regulation of X-Linked Inhibitor of Apoptosis Expression during Ovarian Follicular Development in Vitro
Endocrinology, July 1, 2002; 143(7): 2732 - 2740.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
B. Tian, Y. Zhang, B. A. Luxon, R. P. Garofalo, A. Casola, M. Sinha, and A. R. Brasier
Identification of NF-{kappa}B-Dependent Gene Networks in Respiratory Syncytial Virus-Infected Cells
J. Virol., June 5, 2002; 76(13): 6800 - 6814.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
M. Cejna, J. M. Breuss, H. Bergmeister, R. de Martin, Z. Xu, M. Grgurin, U. Losert, H. Plenk Jr, B. R. Binder, and J. Lammer
Inhibition of Neointimal Formation after Stent Placement with Adenovirus-mediated Gene Transfer of I{kappa}B{alpha} in the Hypercholesterolemic Rabbit Model: Initial Results
Radiology, June 1, 2002; 223(3): 702 - 708.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. J. Chase, M. Bond, M. F. Crook, and A. C. Newby
Role of Nuclear Factor-{kappa}B Activation in Metalloproteinase-1, -3, and -9 Secretion by Human Macrophages In Vitro and Rabbit Foam Cells Produced In Vivo
Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 765 - 771.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Weber, M. Lu, L. Andera, H. Lahm, N. Gellert, M. W. Fariss, V. Korinek, W. Sattler, D. S. Ucker, A. Terman, et al.
Vitamin E Succinate Is a Potent Novel Antineoplastic Agent with High Selectivity and Cooperativity with Tumor Necrosis Factor-related Apoptosis-inducing Ligand (Apo2 Ligand) in Vivo
Clin. Cancer Res., March 1, 2002; 8(3): 863 - 869.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.M. Breuss, M. Cejna, H. Bergmeister, A. Kadl, G. Baumgartl, S. Steurer, Z. Xu, Y. Koshelnick, J. Lipp, R. De Martin, et al.
Activation of Nuclear Factor-{kappa}B Significantly Contributes to Lumen Loss in a Rabbit Iliac Artery Balloon Angioplasty Model
Circulation, February 5, 2002; 105(5): 633 - 638.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Meiners, M. Laule, W. Rother, C. Guenther, I. Prauka, P. Muschick, G. Baumann, P.-M. Kloetzel, and K. Stangl
Ubiquitin-Proteasome Pathway as a New Target for the Prevention of Restenosis
Circulation, January 29, 2002; 105(4): 483 - 489.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
D.L. MANN
The Yin/Yang of Innate Stress Responses in the Heart
Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 363 - 370.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
M. D. Southall, J. S. Isenberg, H. Nakshatri, Q. Yi, Y. Pei, D. F. Spandau, and J. B. Travers
The Platelet-activating Factor Receptor Protects Epidermal Cells from Tumor Necrosis Factor (TNF) alpha and TNF-related Apoptosis-inducing Ligand-induced Apoptosis through an NF-kappa B-dependent Process
J. Biol. Chem., November 30, 2001; 276(49): 45548 - 45554.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
R. V. Sharma, M. V. Gurjar, and R. C. Bhalla
Genome and Hormones: Gender Differences in Physiology: Selected Contribution: Estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappa B activation in VSM cells from female rats
J Appl Physiol, November 1, 2001; 91(5): 2400 - 2406.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Wahl, F. Oswald, U. Simnacher, S. Weiss, R. Marre, and A. Essig
Survival of Chlamydia pneumoniae-Infected Mono Mac 6 Cells Is Dependent on NF-kappa B Binding Activity
Infect. Immun., November 1, 2001; 69(11): 7039 - 7045.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Watanabe, M. Yoshizumi, M. Akishita, M. Eto, K. Toba, M. Hashimoto, K. Nagano, Y.-Q. Liang, Y. Ohike, K. Iijima, et al.
Induction of Nuclear Orphan Receptor NGFI-B Gene and Apoptosis in Rat Vascular Smooth Muscle Cells Treated With Pyrrolidinedithiocarbamate
Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1738 - 1744.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
W. Erl and W. Siess
Sphingosine-1-Phosphate and the Leading Edg-1 of Vascular Smooth Muscle Cells
Circ. Res., September 14, 2001; 89(6): 474 - 476.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Valen, Z.-q. Yan, and G.o. K. Hansson
Nuclear factor kappa-B and the heart
J. Am. Coll. Cardiol., August 1, 2001; 38(2): 307 - 314.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Orlandi, A. Francesconi, D. Cocchia, A. Corsini, and L. G. Spagnoli
Phenotypic Heterogeneity Influences Apoptotic Susceptibility to Retinoic Acid and cis-Platinum of Rat Arterial Smooth Muscle Cells In Vitro : Implications for the Evolution of Experimental Intimal Thickening
Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1118 - 1123.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. MANDERSCHEID, U. K. MEßMER, R. FRANZEN, and J. PFEILSCHIFTER
Regulation of Inhibitor of Apoptosis Expression by Nitric Oxide and Cytokines: Relation to Apoptosis Induction in Rat Mesangial Cells and RAW 264.7 Macrophages
J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1151 - 1163.
[Abstract] [Full Text]


Home page
Eur Heart J SupplHome page
G.K. Hansson
The stabilized plaque: will the dream come true?
Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C69 - C75.
[PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
T.-S. Lee and L.-Y. Chau
Fas/Fas ligand-mediated death pathway is involved in oxLDL-induced apoptosis in vascular smooth muscle cells
Am J Physiol Cell Physiol, March 1, 2001; 280(3): C709 - C718.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. W. Xiao, K. Ash, and B. K. Tsang
Nuclear Factor-{{kappa}}B-Mediated X-Linked Inhibitor of Apoptosis Protein Expression Prevents Rat Granulosa Cells from Tumor Necrosis Factor {{alpha}}-Induced Apoptosis
Endocrinology, February 1, 2001; 142(2): 557 - 563.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J. NEUZIL, T. WEBER, A. SCHRODER, M. LU, G. OSTERMANN, N. GELLERT, G. C. MAYNE, B. OLEJNICKA, A. NEGRE-SALVAYRE, M. STICHA, et al.
Induction of cancer cell apoptosis by {alpha}-tocopheryl succinate: molecular pathways and structural requirements
FASEB J, February 1, 2001; 15(2): 403 - 415.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Rainer de Martin, M. Hoeth, R. Hofer-Warbinek, and J. A. Schmid
The Transcription Factor NF-{kappa}B and the Regulation of Vascular Cell Function
Arterioscler Thromb Vasc Biol, November 1, 2000; 20 (11): e83 - e88.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
A. M. Schmidt and D. M. Stern
Hyperinsulinemia and Vascular Dysfunction: The Role of Nuclear Factor-{kappa}B, Yet Again
Circ. Res., October 27, 2000; 87(9): 722 - 724.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
H. Obara, A. Takayanagi, J. Hirahashi, K. Tanaka, G. Wakabayashi, K. Matsumoto, M. Shimazu, N. Shimizu, and M. Kitajima
Overexpression of Truncated I{kappa}B{alpha} Induces TNF-{alpha}-Dependent Apoptosis in Human Vascular Smooth Muscle Cells
Arterioscler Thromb Vasc Biol, October 1, 2000; 20(10): 2198 - 2204.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. Sadoshima
Cytokine Actions of Angiotensin II
Circ. Res., June 23, 2000; 86(12): 1187 - 1189.
[Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
W. Erl, C. Weber, and G. K. Hansson
Pyrrolidine dithiocarbamate-induced apoptosis depends on cell type, density, and the presence of Cu2+ and Zn2+
Am J Physiol Cell Physiol, June 1, 2000; 278(6): C1116 - C1125.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. J. McCarthy and M. Bennett
The regulation of vascular smooth muscle cell apoptosis
Cardiovasc Res, February 1, 2000; 45(3): 747 - 755.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Walsh and J. M. Isner
Apoptosis in inflammatory-fibroproliferative disorders of the vessel wall
Cardiovasc Res, February 1, 2000; 45(3): 756 - 765.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Chen, L. M. Demers, V. Vallyathan, Y. Lu, V. Castranova, and X. Shi
Involvement of 5'-Flanking kappa B-like Sites within bcl-x Gene in Silica-induced Bcl-x Expression
J. Biol. Chem., December 10, 1999; 274(50): 35591 - 35595.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S.-Y. Hong, W.-H. Yoon, J.-H. Park, S.-G. Kang, J.-H. Ahn, and T. H. Lee
Involvement of Two NF-kappa B Binding Elements in Tumor Necrosis Factor alpha -, CD40-, and Epstein-Barr Virus Latent Membrane Protein 1-mediated Induction of the Cellular Inhibitor of Apoptosis Protein 2 Gene
J. Biol. Chem., June 9, 2000; 275(24): 18022 - 18028.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. M. de Vries, T. A. E. van Achterberg, A. J. G. Horrevoets, J. W. ten Cate, and H. Pannekoek
Differential Display Identification of 40 Genes with Altered Expression in Activated Human Smooth Muscle Cells. LOCAL EXPRESSION IN ATHEROSCLEROTIC LESIONS OF smags, SMOOTH MUSCLE ACTIVATION-SPECIFIC GENES
J. Biol. Chem., July 28, 2000; 275(31): 23939 - 23947.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erl, W.
Right arrow Articles by Weber, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erl, W.
Right arrow Articles by Weber, C.
Related Collections
Right arrow Apoptosis
Right arrow Genomics
Right arrow Smooth muscle proliferation and differentiation